Warning! GuruFocus detected
4 Severe warning signs
with XGN.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Exagen Inc
NAICS : 541380
SIC : 8071
ISIN : US30068X1037
Share Class Description:
XGN: Ordinary SharesDescription
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.96 | |||||
| Equity-to-Asset | 0.21 | |||||
| Debt-to-Equity | 2.41 | |||||
| Debt-to-EBITDA | -2.06 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -7.18 | |||||
| Beneish M-Score | -2.54 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.4 | |||||
| 3-Year EBITDA Growth Rate | 24.9 | |||||
| 3-Year EPS without NRI Growth Rate | 20.9 | |||||
| 3-Year FCF Growth Rate | 18.8 | |||||
| 3-Year Book Growth Rate | -53.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 40.65 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 15.08 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 80.21 | |||||
| 9-Day RSI | 66.79 | |||||
| 14-Day RSI | 58.59 | |||||
| 3-1 Month Momentum % | -30.49 | |||||
| 6-1 Month Momentum % | 20.95 | |||||
| 12-1 Month Momentum % | 114.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.7 | |||||
| Quick Ratio | 2.7 | |||||
| Cash Ratio | 1.63 | |||||
| Days Sales Outstanding | 60.85 | |||||
| Days Payable | 39.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3 | |||||
| Shareholder Yield % | 5.45 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.51 | |||||
| Operating Margin % | -24.51 | |||||
| Net Margin % | -27.17 | |||||
| FCF Margin % | -24.79 | |||||
| ROE % | -91.41 | |||||
| ROA % | -30.8 | |||||
| ROIC % | -97.27 | |||||
| 3-Year ROIIC % | -229.68 | |||||
| ROC (Joel Greenblatt) % | -97.65 | |||||
| ROCE % | -33.35 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.17 | |||||
| PB Ratio | 7.19 | |||||
| Price-to-Tangible-Book | 7.39 | |||||
| EV-to-EBIT | -5.21 | |||||
| EV-to-Forward-EBIT | -9.4 | |||||
| EV-to-EBITDA | -6.01 | |||||
| EV-to-Forward-EBITDA | -1.11 | |||||
| EV-to-Revenue | 1.2 | |||||
| EV-to-Forward-Revenue | 1.12 | |||||
| EV-to-FCF | -4.86 | |||||
| Price-to-GF-Value | 1.33 | |||||
| Price-to-Net-Current-Asset-Value | 57 | |||||
| Earnings Yield (Greenblatt) % | -19.19 | |||||
| FCF Yield % | -19.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Exagen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 55.641 | ||
| EPS (TTM) ($) | -0.83 | ||
| Beta | 2.26 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.03 | ||
| Volatility % | 102.64 | ||
| 14-Day RSI | 58.59 | ||
| 14-Day ATR ($) | 0.46116 | ||
| 20-Day SMA ($) | 3.4165 | ||
| 12-1 Month Momentum % | 114.37 | ||
| 52-Week Range ($) | 1.3003 - 6.22 | ||
| Shares Outstanding (Mil) | 17.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Exagen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Exagen Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Exagen Inc Frequently Asked Questions
What is Exagen Inc(XGN)'s stock price today?
The current price of XGN is $3.99. The 52 week high of XGN is $6.22 and 52 week low is $1.30.
When is next earnings date of Exagen Inc(XGN)?
The next earnings date of Exagen Inc(XGN) is 2025-05-13 Est..
Does Exagen Inc(XGN) pay dividends? If so, how much?
Exagen Inc(XGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers